Johnson & Johnson vs. Danaher: A Comparison of Healthcare Stock Performance Post-Earnings
Johnson & Johnson reported strong Q2 fiscal results for 2026, with sales rising nearly 7% to $25.31 billion and adjusted earnings per share reaching $2.90—both exceeding analyst expectations. The company raised its full-year revenue guidance toward a historic target of over $100 billion in annual revenue. Danaher also posted solid results, driven by improved core growth and high-single-digit EPS gains, with strong performance from its Life Sciences segment despite some project timing delays. Johnson & Johnson's pharmaceutical division was the primary driver behind its success, particularly due to robust sales of newer drugs like Tremfya, which offset a significant decline in revenue for Stelara following patent loss. Danaher’s growth is being fueled by recovery trends in life sciences and bioprocessing demand, with strong order trends indicating underlying strength. While both companies are performing well post-earnings, their long-term risks differ: Johnson & Johnson faces product-specific challenges such as patent expirations, while Danaher deals with broader market uncertainties.